Clinical trials: Insulin
Metabolic Syndrome, Dyslipidemia
Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism
The purpose of this study is to investigate if daily consumption of barley beta-glucans effect lipid and glucose metabolism and alter intestinal microbiota composition in participants with metabolic syndrome or with high risk for…
- Conditions
- Metabolic Syndrome, Dyslipidemia, Obesity, Abdominal, Hyperglycemia
- Trial name
- NCT02041104
- Testing
- Bread with added beta-glucans
- Where
- 3 sites in Slovenia
- Volunteers
- 51 people
- Sponsor
- Mlinotest Zivilska Industrija d.d.
GDM, Insulin Resistance
In Vitro Fertilization Impact on Metabolic Parameters
A quantitative prospective cohort study will be conducted, where blood samples will be collected at different timings during the IVF protocol, to assess the impact of fertility medications on metabolic parameters of patients…
- Conditions
- GDM, Insulin Resistance, Glucose Intolerance, PCOS
- Trial name
- IVF (NCT03426228)
- Testing
- HbA1C
- Where
- United Arab Emirates
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- University of Warwick
Diabetes
Observational Registry for Basal Insulin Treatment Study (ORBIT)
The scientific use of basal insulin is of great help to individuals and the government. However, there are few studies to investigate the real world use, effect, safety and influence factors of basal insulin in China.
- Trial name
- NCT01859598
- Where
- 2 sites in China
- Volunteers
- 19,894 people
- Sponsor
- The George Institute for Global Health, China
Metabolic Syndrome
Canadian Health Advanced By Nutrition and Graded Exercise
The overall objective of the CHANGE initiative is to change the delivery of care in primary care clinics to treat disease by reducing reliance on drugs and hospitals through the promotion of scientifically validated nutritional…
- Trial name
- CHANGE (NCT01616563)
- Testing
- Dietary Intervention, Exercise Prescription and Fitness Program
- Where
- 3 sites in Canada
- Volunteers
- 305 people
- Sponsor
- Daren K. Heyland
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII)…
- Trial name
- HALO-117-406 (NCT03662334)
- Testing
- Rapid Acting insulin with pre-treatment of rHuPH20
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes, Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
- Trial name
- QWINT-5 (NCT05463744)
- Testing
- Insulin Efsitora Alfa, Insulin Degludec
- Where
- 83 sites in United States, Argentina and 5 more
- Volunteers
- 692 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.
- Trial name
- NCT00479258
- Testing
- Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Diabetes, Hypertension
Renal and Hormonal Effects of Pioglitazone
This study examines the effects of pioglitazone on renal sodium handling in subjects prone to insulin resistance, i.e. diabetic and/or hypertensive subjects.
- Trial name
- NCT01090752
- Testing
- Pioglitazone, Metformin
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- University Hospital, Geneva
Alzheimer's Disease
Memory and Insulin in Early Alzheimer's Disease
To determine which parts of the brain are involved in insulin-related memory improvement in early Alzheimer's disease and cognitively normal older adults.
- Trial name
- MAIN (NCT00581867)
- Testing
- Insulin Aspart
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Jeff Burns, MD
Rheumatoid Arthritis, Insulin Resistance
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
The purpose of this study is to determine whether hydroxychloroquine (HCQ) reduces insulin resistance in non-diabetic subjects with rheumatoid arthritis (RA).
- Trial name
- RA PLUS (NCT01132118)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Type 1 Diabetes Mellitus
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
The purpose of this study is to evaluate consistency of accelerated insulin absorption and onset-of-action and shortened duration of action for bolus insulin infusions after pretreatment with 150 units (U) of Hylenex®…
- Trial name
- NCT01526733
- Testing
- Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or…
- Trial name
- NCT01664247
- Testing
- insulin degludec, liraglutide
- Where
- 132 sites in United States, Canada and 9 more
- Volunteers
- 346 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes…
- Trial name
- NCT02688933
- Testing
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Where
- 100 sites in United States, Puerto Rico
- Volunteers
- 638 people
- Sponsor
- Sanofi
Type 2 Diabetes, Renal Insufficiency
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone…
- Trial name
- NCT00911625
- Testing
- 0.5 units/kg daily insulin, 0.25 units/kg daily insulin
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Loyola University
Type 1 Diabetes Mellitus
The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
This randomized, single-blind, 3 arm, parallel group, placebo controlled PK/PD study will enrol 30 Japanese male and female patients with T1DM and age 18 to 65 years, with inadequate glycemic control on insulin defined as HbA1c ≥…
- Trial name
- NCT02582840
- Testing
- Dapagliflozin 5mg, Dapagliflozin 10mg
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
This trial was conducted in Africa, Asia, Europe, North and South America. The aim of the trial was to compare efficacy and safety of insulin degludec and insulin glargine in insulin naïve subjects with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01849289)
- Testing
- Insulin Degludec, Insulin Glargine
- Where
- 81 sites in United States, Brazil and 5 more
- Volunteers
- 833 people
- Sponsor
- Novo Nordisk A/S
Hepatitis C, Chronic, Hepatitis C Virus
Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)
Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
- Trial name
- NCT00705224
- Testing
- Pegylated Interferon, Ribavirin
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult Chinese participants with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT03338023
- Testing
- LY2963016, Lantus®, Insulin Lispro
- Where
- 20 sites in China
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.